A detailed history of Clearbridge Investments, LLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Clearbridge Investments, LLC holds 88,108 shares of RYTM stock, worth $4.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
88,108
Previous 88,108 -0.0%
Holding current value
$4.52 Million
Previous $3.62 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$35.41 - $44.37 $67,137 - $84,125
-1,896 Reduced 2.11%
88,108 $3.62 Million
Q1 2024

May 13, 2024

SELL
$39.12 - $52.44 $45,144 - $60,515
-1,154 Reduced 1.27%
90,004 $3.9 Million
Q4 2023

Feb 09, 2024

SELL
$21.39 - $49.64 $1.96 Million - $4.55 Million
-91,667 Reduced 50.14%
91,158 $4.19 Million
Q3 2023

Nov 13, 2023

BUY
$15.81 - $27.8 $2.89 Million - $5.08 Million
182,825 New
182,825 $4.19 Million
Q3 2020

Nov 12, 2020

SELL
$18.13 - $30.61 $13,126 - $22,161
-724 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$13.16 - $22.9 $315 - $549
-24 Reduced 3.21%
724 $11,000
Q3 2019

Nov 14, 2019

SELL
$18.62 - $24.51 $559,475 - $736,451
-30,047 Reduced 97.57%
748 $16,000
Q1 2019

May 15, 2019

BUY
$24.76 - $31.66 $74 - $94
3 Added 0.01%
30,795 $844,000
Q4 2018

Feb 14, 2019

SELL
$24.11 - $31.34 $361 - $470
-15 Reduced 0.05%
30,792 $828,000
Q3 2018

Nov 14, 2018

SELL
$26.99 - $35.85 $1,268 - $1,684
-47 Reduced 0.15%
30,807 $899,000
Q2 2018

Aug 14, 2018

SELL
$17.02 - $35.2 $126,118 - $260,832
-7,410 Reduced 19.37%
30,854 $964,000
Q1 2018

May 15, 2018

BUY
$19.9 - $32.25 $725,872 - $1.18 Million
36,476 Added 2040.04%
38,264 $761,000
Q4 2017

Feb 14, 2018

BUY
$22.0 - $30.51 $39,336 - $54,551
1,788
1,788 $52,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $2.86B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Clearbridge Investments, LLC Portfolio

Follow Clearbridge Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearbridge Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clearbridge Investments, LLC with notifications on news.